Try our Advanced Search for more refined results
Life Sciences
-
April 06, 2026
WilmerHale Adds Regulatory Atty From Mayer Brown In DC
WilmerHale announced Monday it has hired a veteran U.S. Food and Drug Administration and life sciences regulatory attorney from Mayer Brown LLP.
-
April 06, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court's docket this past week featured a mix of high-profile corporate disputes, insider trading allegations, contract fights and significant rulings shaping fiduciary duty and deal litigation.
-
April 06, 2026
Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy
Neurocrine Biosciences has agreed to acquire biotechnology company Soleno Therapeutics for about $2.9 billion in cash, in a deal advised by Cooley LLP and Wilson Sonsini Goodrich & Rosati PC, the companies said on Monday.Â
-
April 03, 2026
Case-By-Case Guide As Justices Eye Landmark Pharma Law
Drugmakers and prominent allies are inundating the U.S. Supreme Court with calls to scrutinize Medicare's new power to slash payments by tens of billions of dollars, and the justices look poised to take up or turn down a fistful of legal challenges in one fell swoop.
-
April 03, 2026
Barnes & Thornburg Snags PFAS Expert From Venable
Barnes & Thornburg LLP is beefing up its product liability and mass torts practice with the addition of a Venable LLP partner known for representing and counseling companies in environmental and toxic tort-related matters, including issues involving so-called forever chemicals, the firm announced Thursday.
-
April 03, 2026
SEC Moves To Set Up $40M Investor Fund In Cassava Case
The U.S. Securities and Exchange Commission asked a Texas federal court on Friday to establish a $40 million fund to potentially compensate investors harmed by a Texas biopharmaceutical company and two former executives' alleged misstatements about an Alzheimer's drug, following the company's 2024 settlement with the regulator.
-
April 03, 2026
Legislative Update: Cannabis And Psychedelics Bill Roundup
State lawmakers in Delaware and West Virginia advanced legislation to more tightly regulate kratom products, Missouri and Kentucky legislators considered bills to fund research into the therapeutic uses of the psychedelic ibogaine, and Idaho's Legislature came together to urge voters to reject a medical marijuana legalization proposal that could be on the ballot this November. Here are the major moves in cannabis and psychedelics legislation from the past week.
-
April 03, 2026
EPA Eyes Microplastics, Drugs For Drinking Water Watch List
The U.S. Environmental Protection Agency is looking to include microplastics and pharmaceuticals in its drinking water contaminants list for the first time, the agency has announced in a move it says could make the proposed contaminants a consideration in regulatory action.
-
April 03, 2026
Law360 Announces The Members Of Its 2026 Editorial Boards
Law360 is pleased to announce the formation of its 2026 Editorial Advisory Boards.
-
April 03, 2026
Aetna Escapes COVID Testing Payment Suit In Calif.
A Nebraska testing laboratory failed to prove that Aetna underpaid more than $53 million for COVID-19 testing services, a California federal judge has ruled, dismissing the lab's federal racketeering and state law claims against the insurer but leaving the door open to an amended suit.Â
-
April 03, 2026
NYC Fights Sanctions Over Discovery In IVF Sex Bias Dispute
New York City urged a federal judge to reject a gay couple's sanctions bid in their suit claiming a municipal health plan blocked them from receiving in vitro fertilization coverage out of discrimination, calling their concerns with the city's sluggish discovery production in the case premature.
-
April 03, 2026
Caterpillar Worker's Bankruptcy Dooms Genetic Privacy Claim
An Illinois federal judge has thrown out a Caterpillar Inc. employee's proposed class genetic privacy suit over allegedly illegal medical history probes, saying the worker's midcase Chapter 7 bankruptcy filing means the claims now belong to his bankruptcy estate and not to him personally.
-
April 02, 2026
Georgia Midwifery Laws Violate State Constitution, Suit Says
A trio of midwives are challenging Georgia laws that restrict their ability to practice, arguing that the statutes exacerbate an ongoing maternal health crisis and conflict with the Peach State's constitution.Â
-
April 02, 2026
Squires Gives Go-Ahead To 5 Patent Reviews, Denies 8
In the latest order summarizing his decisions on requests for America Invents Act patent reviews, U.S. Patent and Trademark Office Director John Squires has granted five petitions and turned down eight others.
-
April 02, 2026
Petition To Repeal Legal Pot Mobilizes A Showdown In Mass.
A campaign to repeal the legalization of retail cannabis in Massachusetts via ballot initiative — the first campaign of its kind in the country — is uniting legalization advocates, entrepreneurs and industry players in a coordinated response to defeat the effort before it spreads to other states.
-
April 02, 2026
Ex-Pharma Exec Hit With $5.3M Fee Award In Del.
The Delaware Chancery Court has ordered a former pharmaceutical executive to pay more than $5.3 million in attorney fees following years of litigation over alleged disloyal conduct and trade secret misuse, concluding that the award is reasonable despite objections that the amount was excessive.
-
April 02, 2026
Alexion Beats Trade Secret Claims In Amyndas Suit
Amyndas Pharmaceuticals failed to specifically identify the trade secrets it claimed pharmaceutical company Alexion learned of during early partnership talks and improperly used to launch a business collaboration with another competitor, a Massachusetts federal judge has found.
-
April 02, 2026
Trump Orders 100% Pharma Tariff, Modifies Metals Duties
Later this year, the U.S. will impose 100% tariffs on imported pharmaceuticals, but drug companies could qualify for reduced tariff rates as low as zero if they agree to invest domestically and enter most-favored-nation drug-pricing agreements with the government, according to an executive order President Donald Trump signed Thursday.
-
April 02, 2026
Snell & Wilmer Names Life Sciences Pro As San Diego Leader
Snell & Wilmer LLP has tapped a longtime corporate attorney who specializes in the life sciences industry to be the new head of its San Diego office.
-
April 02, 2026
Teva $35M Delayed Generic Inhalers Deal Gets Initial OK
A Massachusetts federal judge Thursday granted initial approval to a $35 million deal that Teva Pharmaceuticals agreed to pay to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers.
-
April 02, 2026
Vape Sellers, Makers Evade Ga. Woman's RICO Scheme Suit
A Georgia federal judge has tossed a suit against numerous vape sellers and makers alleging they conspired to sell vapes with illegal levels of delta-9 THC, saying her complaint fails to allege any kind of scheme, but rather amounts to describing the normal supply chain.
-
April 01, 2026
Ex-Wilson Sonsini M&A Co-Head Rejoins Goodwin In SF
A former partner at Goodwin Procter LLP's Silicon Valley office has rejoined the firm in San Francisco after co-leading Wilson Sonsini Goodrich & Rosati PC's mergers and acquisitions practice for five years, Goodwin announced on Wednesday.
-
April 01, 2026
7th Circ. Says Ill. BIPA Amendment Applies Retroactively
The Seventh Circuit held Wednesday that a liability-limiting amendment to Illinois' biometric privacy law applies to every lawsuit pending at the time the amendment took effect, ruling that the amendment is only a procedural change to the law and, therefore, must be applied retroactively.
-
April 01, 2026
Berkshire Must Defend Trulieve In Worker Death Suit
An insurance company that is a unit of Berkshire Hathaway had an obligation to defend Trulieve Inc. against a Massachusetts wrongful death lawsuit brought by the family of a cannabis worker, a Florida federal judge has ruled, rejecting arguments that the worker wasn't an employee.
-
April 01, 2026
3 Federal Circuit Clashes To Watch In April
The Federal Circuit argument calendar for this month includes Centripetal Networks' appeal of a decision clearing Cisco of infringing cybersecurity patents after a multibillion-dollar award was thrown out, as well as Ecobee's challenge to an $11.5 million infringement verdict involving smart thermostats.
Expert Analysis
-
Series
Watching Hallmark Movies Makes Me A Better Lawyer
I realize you may be judging me for watching, and actually enjoying, Hallmark Channel movies, but the escapism and storylines actually demonstrate qualities and actions that lead to an efficient, productive and positive legal practice, says Karen Ross at Tucker Ellis.
-
New Orphan Drug Law Provides A Key Fix For Pharma Cos.
The Consolidated Appropriations Act enacted last month restores the U.S. Food and Drug Administration's long-standing interpretation of "same disease or condition," related to orphan drug exclusivity, resolving years of regulatory uncertainty and litigation that have discouraged rare disease research, say attorneys at Spencer Fane.
-
When Trade Secret Litigation And Criminal Law Collide
An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.
-
Opinion
PTAB Needs Reform To Protect Inventors From Larger Cos.
The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.
-
FDA User Fee Talks Offer Clues On Upcoming Reforms
As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.
-
Moderna Case Highlights Overlooked Hurdle In Biopharma IP
The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.
-
FDA Framework For Personalized Therapies Raises Questions
The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.
-
Emissions Permits May Not Override Pollution Exclusions
Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.
-
5 Tips For Navigating Your Firm's All-Attorney Summit
Excerpt from Practical Guidance
Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.
-
Series
Coaching Soccer Makes Me A Better Lawyer
Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.
-
Series
Law School's Missed Lessons: The Human Element
Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.
-
Avoid The Unexpected When Drafting License Agreements
The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.
-
CMS Healthcare Enforcement Initiatives May Cause Disruption
The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.
-
The Benefits Of Choosing A Niche Practice In The AI Age
As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.
-
How PBMs Can Adapt To Plan Sponsors' Disclosure Demands
As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.